Oslo, Norway, July 3, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, has posted an updated company presentation
for July 2023 on its webpage. The presentation is also attached hereto. 

Going forward, the latest company presentation will be available at:
https://nykode.com/investors/financial-reports-and-presentations/ 


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses and elicit
efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive efficacy and safety results from its Phase 2 trial for the
treatment of cervical cancer